<DOC>
	<DOCNO>NCT02760264</DOCNO>
	<brief_summary>The purpose study determine whether new medication call vamorolone safe well-tolerated boy Duchenne muscular dystrophy ( DMD ) age ≥ 4 &lt; 7 year old .</brief_summary>
	<brief_title>A Study Assess Vamorolone Boys With Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>This study evaluate safety tolerability new steroid-like medication call vamorolone boy DMD age ≥ 4 year &lt; 7 year . Enrolled participant take study medication 14 day follow 14 day follow-up period . The potential effectiveness vamorolone treat DMD also explore .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Subject 's parent legal guardian provide write informed consent/Health Insurance Portability Accountability Act ( HIPAA ) authorization prior studyrelated procedure ; 2 . Subject confirm ( Central Genetic Counselor ) diagnosis DMD define : 1 . Dystrophin immunofluorescence and/or immunoblot show complete dystrophin deficiency , clinical picture consistent typical DMD , OR 2 . Identifiable mutation within DMD gene ( deletion/duplication one exon ) reading frame predict 'outofframe ' , clinical picture consistent typical DMD , OR 3 . Complete dystrophin gene sequence show alteration ( point mutation , duplication , ) expect preclude production dystrophin protein ( i.e . nonsense mutation , deletion/duplication lead downstream stop codon ) , typical clinical picture DMD ; 3 . Subject ≥ 4 year &lt; 7 year age time enrollment study ; 4 . Subject able complete Time Stand Test ( TTSTAND ) without assistance , assess Screening Baseline Visits ; 5 . Clinical laboratory test result within normal range Screening Visit , abnormal , clinically significant , opinion Investigator . ( Note : Serum gamma glutamyl transferase [ GGT ] , creatinine , total bilirubin must ≤ upper limit normal range Screening Visit ) ; 6 . Subject evidence chicken pox immunity determine presence IgG antibodies varicella , document positive test result test laboratory Screening Visit ; 7 . Subject parent/guardian willing able comply schedule visit , study drug administration plan , study procedure . 1 . Subject current history major renal hepatic impairment , diabetes mellitus immunosuppression ; 2 . Subject current history chronic systemic fungal viral infection ; 3 . Subject acute illness within 4 week prior first dose study medication ; 4 . Subject use mineralocorticoid receptor agent , spironolactone , eplerenone , canrenone ( canrenoate potassium ) , prorenone ( prorenoate potassium ) , mexrenone ( mexrenoate potassium ) within 4 week prior first dose study medication ; 5 . Subject evidence symptomatic cardiomyopathy . [ Note : Asymptomatic cardiac abnormality investigation would exclusionary ] ; 6 . Subject currently treat receive previous treatment oral glucocorticoid immunosuppressive agent . [ Notes : Past transient use oral glucocorticoid oral immunosuppressive agent longer 3 month cumulative , last use least 3 month prior first dose study medication , consider eligibility casebycase basis . Inhaled and/or topical corticosteroid prescribe indication DMD permit must administer stable dose least 3 month prior study drug administration ] ; 7 . Subject use idebenone within 4 week prior first dose study medication ; 8 . Subject allergy hypersensitivity study medication constituent ; 9 . Subject severe behavioral cognitive problem preclude participation study , opinion Investigator ; 10 . Subject previous ongoing medical condition , medical history , physical finding laboratory abnormality could affect safety , make unlikely treatment followup correctly complete impair assessment study result , opinion Investigator ; 11 . Subject take investigational drug currently take investigational drug within 3 month prior start study treatment ; 12 . Subject previously enrol study .</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>vamorolone</keyword>
</DOC>